Tissue plasminogen activator: why the backlash?
Publication
, Journal Article
Topol, EJ; Califf, RM
Published in: J Am Coll Cardiol
June 1989
Duke Scholars
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
June 1989
Volume
13
Issue
7
Start / End Page
1477 / 1480
Location
United States
Related Subject Headings
- Tissue Plasminogen Activator
- Streptokinase
- Recombinant Proteins
- Random Allocation
- Placebos
- Myocardial Infarction
- Humans
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Topol, E. J., & Califf, R. M. (1989). Tissue plasminogen activator: why the backlash? J Am Coll Cardiol, 13(7), 1477–1480. https://doi.org/10.1016/0735-1097(89)90335-5
Topol, E. J., and R. M. Califf. “Tissue plasminogen activator: why the backlash?” J Am Coll Cardiol 13, no. 7 (June 1989): 1477–80. https://doi.org/10.1016/0735-1097(89)90335-5.
Topol EJ, Califf RM. Tissue plasminogen activator: why the backlash? J Am Coll Cardiol. 1989 Jun;13(7):1477–80.
Topol, E. J., and R. M. Califf. “Tissue plasminogen activator: why the backlash?” J Am Coll Cardiol, vol. 13, no. 7, June 1989, pp. 1477–80. Pubmed, doi:10.1016/0735-1097(89)90335-5.
Topol EJ, Califf RM. Tissue plasminogen activator: why the backlash? J Am Coll Cardiol. 1989 Jun;13(7):1477–1480.
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
June 1989
Volume
13
Issue
7
Start / End Page
1477 / 1480
Location
United States
Related Subject Headings
- Tissue Plasminogen Activator
- Streptokinase
- Recombinant Proteins
- Random Allocation
- Placebos
- Myocardial Infarction
- Humans
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology